SLC5A2 and diabetes mellitus: Thus the comparative effectiveness of SGLT-2 inhibitors versus alternative second line oral antidiabetic treatments on outcomes important to people with type 2 diabetes mellitus, particularly reduction in HbA1c level, remains unclear.